Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - fentanyl citrate, quantity: 78.6 microgram/ml (equivalent: fentanyl, qty 50 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride; sodium citrate dihydrate; citric acid - indications as at 31 july 2003: short duration analgesia during pre-medication, induction and maintenance of anaesthesia, and in the immediate post operative period. opioid analgesic supplement to general and regional anaesthesia. combination with a neuroleptic as an anaesthetic pre medication for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - sodium chloride, quantity: 200 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - indications as at 19 february 1993 : as an additive to parenteral fluids in patients who have specific electrolyte needs. as a sclerosing agent for small symptomatic varicose veins.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - neostigmine methylsulfate -

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

astrazeneca limited - pancuronium bromide 2 mg/ml - solution for injection - 4 mg/2ml - active: pancuronium bromide 2 mg/ml excipient: acetic acid sodium acetate trihydrate sodium chloride sodium hydroxide water for injection - an adjunct to surgical anaesthesia to induce skeletal muscle relaxation to facilitate operative manipulations. the necessary conditions for intubation can be achieved with pancuronium alone or following suxamethonium. to promote mechanical ventilation by reducing or eliminating spontaneous breathing effort in intensive care patients.

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antithrombotic agents - brilique, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients withacute coronary syndromes (acs) ora history of myocardial infarction (mi) and a high risk of developing an atherothrombotic eventbrilique, co-administered with acetyl salicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

astrazeneca ab - exenatide - diabetes mellitus, type 2 - drugs used in diabetes - bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations).bydureon is indicated for treatment of type 2 diabetes mellitus in combination with:metforminsulphonylureathiazolidinedionemetformin and sulphonylureametformin and thiazolidinedionein adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

astrazeneca ab - exenatide - diabetes mellitus, type 2 - drugs used in diabetes - byetta is indicated for treatment of type-2 diabetes mellitus in combination with:metformin;sulphonylureas;thiazolidinediones;metformin and a sulphonylurea;metformin and a thiazolidinedione;in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (copd) (fev1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.,

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - breast neoplasms - endocrine therapy, anti-estrogens - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy., , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. , in pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (lhrh) agonist.,